贝伐珠单抗治疗创伤性脑水肿后血脑屏障结构变化的实验研究
该研究将70只大鼠随机分为对照组、假手术组、TBI组、TBI+生理盐水组和TBI+贝伐珠单抗组,于TBI后24小时检测VEGF与occludin表达、观察脑水肿与血脑屏障结构。结果示TBI后VEGF表达升高,贝伐珠单抗抑制VEGF表达;MRI示贝伐珠单抗治疗缩小脑水肿和强化范围,同时减轻血管源性和细胞内水肿;贝伐珠单抗使occludin表达上调、IgG强度下调,血脑屏障结构损伤程度减轻。作者结论为贝伐珠单抗通过修复血脑屏障损伤促进创伤性脑水肿恢复,是TBI治疗的潜在药物。
要点
- 大鼠TBI后24小时VEGF表达升高,贝伐珠单抗治疗可抑制VEGF表达。
- MRI示TBI后创伤灶周围出现明显脑水肿和强化区,贝伐珠单抗治疗使脑水肿和强化范围均缩小。
- TBI后出现血管源性和细胞内水肿,贝伐珠单抗治疗同时减轻这两种类型的水肿。
- TBI后occludin表达下调、IgG强度上调、血脑屏障结构受损,贝伐珠单抗治疗后occludin上调、IgG下调、血脑屏障结构损伤程度减轻。
- 作者认为贝伐珠单抗通过修复血脑屏障损伤促进创伤性脑水肿恢复,是TBI治疗的潜在药物。
适用人群与场景
- 大鼠创伤性脑损伤模型,于TBI后24小时进行检测
研究设计与关键结果
- 研究类型为动物实验,70只大鼠随机分为对照组、假手术组、TBI组、TBI+生理盐水组和TBI+贝伐珠单抗组。
- TBI后VEGF表达升高,贝伐珠单抗抑制VEGF表达。
- MRI示TBI后创伤部位周围出现明显脑水肿和强化区,贝伐珠单抗治疗使脑水肿和强化范围均缩小。
- 与假手术组相比,TBI后出现血管源性和细胞内水肿,贝伐珠单抗治疗同时减轻这两种类型的水肿。
- TBI后occludin表达下调、IgG强度上调、血脑屏障结构受损;贝伐珠单抗治疗后occludin表达上调、IgG强度下调,血脑屏障结构损伤程度减轻。
证据类型、等级与局限
- 证据类型:动物实验(大鼠)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐,作者认为贝伐珠单抗通过修复血脑屏障损伤促进创伤性脑水肿恢复,是TBI治疗的潜在药物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effect of bevacizumab on traumatic cerebral edema and its relationship with the blood-brain barrier (BBB) in traumatic brain injury (TBI).
METHODS: Seventy rats were randomly divided into the control, sham, TBI, TBI + normal saline (TBI-NS), and TBI + bevacizumab (TBI-Beva) groups. A total of 24 h after TBI, western blotting was used to detect vascular endothelial growth factor (VEGF) and occludin. Pathological examination was used to observe cerebral edema. Magnetic resonance imaging (MRI) was performed to observe cerebral edema and brain tissue enhancement. Transmission electron microscope was used to observe the structure of BBB. Immunofluorescence was used to detect immunoglobulin G (IgG) intensity.
RESULTS: The expression of VEGF increased after TBI, whereas bevacizumab inhibited the expression of VEGF. MRI showed obvious cerebral edema and enhancement areas around the trauma site after TBI, and bevacizumab treatment reduced both the cerebral edema and enhancement range. Compared with the Sham group, cerebral edema occurred after TBI, including vasogenic and intracellular edema, but bevacizumab treatment simultaneously reduced both types of cerebral edema. The expression of occludin was down-regulated and IgG intensity was up-regulated, and the BBB structure was damaged after TBI. The expression of occludin was up-regulated and IgG intensity was down-regulated after treatment with bevacizumab. Meanwhile, the extent of damage to the BBB structure was reduced.
CONCLUSION: Bevacizumab promotes recovery from traumatic cerebral edema by repairing BBB damage and is a potential drug for TBI treatment.
参考来源
- Lin XY, Usman M, Ai L, et al. Experimental Study on Changes in the Structure of the Blood-Brain Barrier after Treatment with Bevacizumab for Traumatic Cerebral Edema. Neurocrit Care. 2026. PMID: 41673382. doi:10.1007/s12028-026-02458-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。